Significance of CSE-1034 (Eloresâ„¢) in Treatment of Urinary Tract Infections due to Multi Drug Resistant ESBLPositiveEscherichia coli
UTIs are one of the most common infections of geriatric patients in community acquired and hospital acquired settings. Escherichia coli(E. coli) is usually the most common pathogen responsible for UTI.Antibiotic resistance is the main reason for failure of therapy especially in E. coli. Biofilm formation, ESBL and MBL production&efflux pump over expression are the main reasons for antibiotic resistance in E. coli. That's why management of UTI with multi drug resistant (MDR)E. coli has always been challenge for the clinicians.
We are reporting empiric use of new antibiotic adjuvant entity Eloresâ„¢(Ceftriaxone/ Sulbactam/Disodium-edetate) in the management of UTIs caused by multi drug resistant E. coli.
2. Rowe TA, Juthani-Mehta M. Urinary tract infection in older adults. Aging health 2013;9(5).
3. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JC, Dolin R, editors. Mandell, Douglas, and Bennettâ€™s: Principles and Practice of Infectious Disease. 7th edition. PA, USA: Elsevier; 2010. p. 957-85.
4. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM; Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40(5):643-54.
5. Wada K, Uehara S, Yamamoto M, Sadahira T, Mitsuhata R, Araki M, et al. Clinical analysis of bacterial strain profiles isolated from urinary tract infections: A 30-year study. J Infect Chemother 2016;22(7):478-82.
6. Stefaniuk E, Suchocka U, Bosacka K, Hryniewicz W. Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland. Eur J Clin Microbiol Infect Dis 2016;35(8):1363-9.
7. Chaudhary M, Kumar S, Payasi A. Prevalence and antimicrobial sensitivity of extended spectrum spectrum Î²-lactamase producing gram negative bacteria from clinical settings in India from 2010-2012. Int J Med Med Sci 2013;46:1212-7.
8. Chaudhary M, Payasi A. Prospective study for antimicrobial susceptibility of Escherichia coli isolated from various clinical specimens in India. J Microb Biochem Technol 2012;4:157-60.
9. Chaudhary M, Payasi A. Changing trends of commonly used intensive care unit antibiotics due to differential membrane permeability in resistant Escherichia coli collected in EASE programme. J Microb Biochem Technol 2013;5:84-7.
10. Spurbeck RR, Stapleton AE, Johnson JR, Walk ST, Hooton TM, Mobley HL. Fimbrial profiles predict virulence of uropathogenic Escherichia coli strains: Contribution of ygi and yad fimbriae. Infect Immun 2011;79:4753-63.
11. Chaudhary M, Payasi A. A randomized, open-label, prospective, multicenter phase-III clinical trial of Elores in lower respiratory tract and urinary tract infections. J Pharm Res 2013;6:409-14.
12. Saha S, Nayak S, Bhattacharyya I, Saha S, Mandal AK, Chakraborty S, et al. Understanding the patterns of antibiotic susceptibility of bacteria causing urinary tract infection in West Bengal, India. Front Microbiol 2014;5:463.
13. Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D. The participants of the 3rd World Healthcare - Associated Infections Forum. Ready for a World without antibiotics? The Pensieres antibiotic resistance call to action. Antimicrob Resist Infect Control 2012;1:1-13.
14. Chaudhary M, Kumar S, Payasi A. Novel approach to combat acquired multiple resistance in Escherichia coli by using EDTA as efflux pump inhibitor. J Microb Biochem Technol 2012;4:126-30.
15. Chaudhary M, Kumar S, Payasi A. Role of CSE1034 in Escherichia coli biofilm destruction. J Microb Biochem Technol 2013;5:54-8.
16. Elores Monograph. Venus Medicine Research Centre, Baddi India; 2016.
17. Grabe M, Bartoletti R, Bjerklund-Johansen TE, Cai T, Cek M, Koves B, et al. Guidelines on urological infections. Eur Assoc Urol 2015:1-86. http://uroweb.org/wp-content/uploads/19- Urological infections_LR2.pdf. (Accessed on August 21, 2016).
18.Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48(12):1724-8.
19. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, HonorÃ© PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011;1:14.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.